Antiplatelet Agents
คำสำคัญ:
-บทคัดย่อ
-
Downloads
เอกสารอ้างอิง
Tnplett DA. Hemostasis A Case Oriented Approch. New York: Igaku-Shoin, 1985.
Ware JA, Coller BS. Platelet morphology, biochemistry, and function. In. Beutler E, Lichtman MA, Coller BS, Kipps,eds. Williams Hematology. 5th ed. New York: McGraw-Hill, Inc., 1995:1161-201.
Cohen I, Gerrard JM, Bergman RN, et al. The role of contractile filaments in platelet activation. In: Pacters H. ed. Protides of the Biological Fluids: Colloquium 26. Oxford: Pergamon Press, 1979:555-6.
Nieuwenhais HK, Sakariassen KS, Hoddjik WPW, et al Deticiency of platelet membrane glycoprotein la associated with a decreased platelet adhesion to sub-endothelium: A defect in platelet spreading. Blood 1986;68:692-5.
Turitto VT, Weiss HJ, Zimmerman TS, Susman II. Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood 1986,68:823.
Piotrowicz RS, Orchekowski RP, Nugent DJ, et al. Glycoprotein Ic/ia fnuctions as an activation-indepent fibronectin receptor on human platelets. J Cell Biol 1988;106:1359-64.
Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand's disease. Blood 1987;70:895.
Nichols WL, Gerrard JM, Didisheim P. Platelet structure, biochemistry and physiology. In: Poller L, ed. Recent Advance in Blood Coagulation. Edinburgh: Churchill Livingstone, 1981:1-39.
Berndt MC, Gregory C, Dowden G, et al. Thrombin interactions with platelet membrane protein. Ann NY Acad Sci 1986;485:374-86.
Sixma JJ, Wester J. The hemostatic plug. Semin Hematol 1977;14:265.
Cliveden PB, Salzam EW. Platelet metabolism and the effect of drugs. In: bowie EJW, Shap AA. Hemostasis and Thrombosis. London: Butterworths. 1985:1-35.
Bell RL, Kennerly DA, Stanford H, Majerus PW. Diglyeridelipase: a pathway for aracidonic acid release from human platelets. Proc Nat! Acad Sci USA 1979;76:3238-41.
Ritten house-Simmons S. Indomethacin-induced accumulation of diglyceride in activated human platelets. The role of diglyceride ipase. J Biol Chem 1980;255:2259-62.
Winocour PD, Kinlough-RL, Mustard JF. Effect of the phospholipase A inhibitor mepacrine on aggreggation of washed rat platelets. Fed Proc 1979;38:1271.
Hong S-C L, Levine L. Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc Natl Acad Sci USA 1976;73:1730-4.
Nelson WR, Taylor GA. In vitro inhibition of endotoxin-induced platelet aggregation with hydrocortisone sodium succinate (Solu-Cortef). Scand J Haematol 1975;15:35-44.
Blajchman MA, Senyi AF, Hirsh J, et al. Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the w=vessel wall. J clin Invest 1979;63:1026-35.
Cheung WY. Calmodulin plays a pivotal role in cellular grgulation. Science 1979;207:19-27.
Klee CB, Crouch TB, Richman PG Calmodulin. Ann Rew Biochem 1980;49:489-515.
Low PS, Lloyd DH, Stein TM, Rogers JA. Calcium displacement by local anesthetics. Dependence an pH and anesthetic charge. J Biol chem 1979;254:4199-25.
Wong PYK, Chemg WY. Calmodulin stimulates human platelet phospholipase A . Biochem Biophys Res Comu 1979;90:473-80.
Gerrard JM, White JG, Rao GHR, Townsend D. Localization of platelet prostaglandin production in the platelet dense tubular system. Am J Pathol 1976,83:283-98.
Smith JB, Willis AL. Aspirin selectively inhits prostaglandin production in human platelets. Nature 1971;231:235-7.
Roth GJ, Stanford N, Majerus PW. Acetlylation of prostagiandin synthesis by aspirin, Proc Nati Acad Sci USA 1975;72:3073-6.
Ali M, Mcdunald JWD. Reversible and irreversible inhibition of platelet cyclooxygenase and serotonin release by non-steroidal antinflammatory drugs. Thromb Res 1978;13:1057-65.
Marcus AJ, Weksler BB, Jaffe EA, Braekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980;66:979-86.
Needleman P, Raz A, Ferrendelli JA, Minkes M. Application of imidozole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Nti Acad Sci USA 1977;74:1716-20.
Hokama Y, Morita AH, Abad MA, et al. Effect of levamisole on aggregation of platelet stimulated with compounds associated with the prostaglandin synthetic pathway. Res Commu Clem Pathol Phramacol 1978;19:141-9.
Lebreton GC, Venton DL, Enke SE, Halusha PV. 13-Azaprostanoic acid: a specific antagonist of human blood platelet thromboxan/ebdoperoxides receptor. Proc Natl Acad Sci USA 1979;76:4097-1001.
Weiss HJ, Turitto VT. Prostacyclin (Prostaglandin 12, PGI) inhibits platelet adhesion and thrombus formation on subendothelium, Blood 1979,53:244-50.
Ehrman M, Jaffe EA, Weksler BB Prostacyclin (PGI) inhibits the development in platelets of ADP and arcahidonate-mediated shape change and procoagulant activity. Cire Res 1979;27:293a.
Sozekiik J, Szczekik A, Mizankovaski R Haemodynamic changes indduced by prostacyclin in man. Br Heart J 1979;44:254-8.
Mills DCB, Smith JP. The influence on pletelet aggregation of durgs that affect the accumulation of adenosine 3:5 -cycic mononophosphate in platelets. Biochem J 1971;121:185-96.
Moncoda S, Korbut R. Dipyridamole and other phosphodiesterase inhibitor act as antithrombotic agents by potentiating endogenus prostacyclin. Lancet 1978;1:1286-9.
Lyons RM, Show JD. Interaction of Ca' and protein phospharylation in the rabbit platelet release reaction. J Clin Invest 1980;65:242-55.
Steer MI, Wood A. Regulation of human platelet adenylate cyclase by epinephrine, prostaglandin E1. and guanidine nucloetides J Biol Chem 1979,254:10791-7.
Shattil SJ, Bennett JS, McDonough M, Turnbull J. Carbenicillin and penicillin G inhibit platet function in vitro by impairing the interaction of agonists with the platelet surface. J clin Invest 1980;65:329-37.
Ts'ao CH, Drajewski DV. Effect of dextran on platelet activation by polymerizing fibrin. Am J Pathol 1982;106:1-7.
Dyerberg J, Bang HO. Haemostatic function and polyunstarated fatty acids in Eskimoes. Lancet 1979;2:433-5.
Conrad J, Lecrabier C, Scarabin PY, et al. Effects of long-term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980;20:143-8.
David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticllpidine on platelet function in mormal subjects. Throm Res 197979;14:35-49
Favis GR, Colman RW. The action of halofenate on platelet shape change and prostaglandin synthesis. J Lab Clin Med 1978;92:409-16.
Ortega MP, Sunkel C, Armjo M, Priego JG. Eifects of etofibrate on platelet function: in vitro studies in human plasma. Thromb Res 1980;19:409-16.
Weksler BB, Gillick M, Pink J. Effect of propanolol on platelet function. Blood 1977;49:185-96.
Rossi Ec, Levin NW. Inhibition of ADP-induced platelet aggregation by furosemide. J lab Clin Med 1973;81:140-7.
Rossi EC, Levin NW. Inhibiton of primary ADP-induced platelet aggregation in normal subjects after adminestration of nitorfurantion. J Clin Invest 1973;52:2457-67.
Saxon A, Kattlove HE. Platelet inhibition by sodium nitroprusside, a smooth muscle inhibitor. Blood 1976;47:957-61.
Walenga R, Vanderhock JK, Feinstein MB, Serine esterose inhibitors block stimulus-induced mobilization of arachidonic acid and phosphatidyl inoside-specific phospholipase Cactivity in platelet. J Biol Chem 1980;255:6024-7.
Lin DC, Tobin KD, Grumet M, Lin S. Cytochalasins inhibit nuclei-induced actin polymerization by blocking filament elogation. J Clin Biol 1980;84:455-60.
Antiplatelet Trialists' Collaboation. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-31.
Antiplatelet Trialists' Collaboation Collabolative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy invarious cetegories of patients. Br Med J 1994,308:81-106.
Dalen JE, Hirsh J. Third ACCP conferance on anti-thrombotic therapy. Chest 1995;98:1S-1748.
Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-anthrombin in II but is susceotible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antitithrombin D-phenylalanyi-L-prolyl-L-aryinyl chlomethyiketone. Proc Nati Acad Sci USA 1988;85:3184-8.
Harker LA, Maraganore JM, Hirsh J Novel antithrombotic agents. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice 3rd ed. Philadelphia: JP Lippincott, 1994;1638-60.
Harker LA, Kelly AB, Hanson SR, et al Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in non human primates. Circulation 1993,87:1017-29.
Harker LA, Hamson SR, Kelly AB, et al. Prevention of injury-induced vascular stenosis by transient inhibition of tissue factor (TF)-dependent thrombus formation. Thromb Haemost 1995.
Hanson SR, Pareti Fl, Ruggeri ZM, et al. Effects of monoclonal antibodies against the platelet gycoprotein Jib/IIla complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988;81:149-58.
Coller BS, Anderson K, Weisman HF. New antiplatelet agents: Platelet GP lib/Illa antagonists. Thromb Haemost 1995;74:302-8.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein lib/lla receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
Harker LA. Platelets and vascular thrombosis. N Engl J Med 1994;330:1006-7.
Kleinman NS, Ohman ME, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: results of the TAMI 8 pilot study. J AM Coll Cardiol 1993;22:318-9.
Topol ET, Calff RM, Weisman HF, et al Randomized trial of coronary intervention with antibody against platelet lib/Ila intregrin for reduction of clinical restenosis: Results at six months. Lancet 1994:343:881-6.
Simoons ML, Lan de Boer M, Brand M, et al. Randomized trial of a lib/Illa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
Friksson BI, Kalebo P,Ekman S, et al. Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin, CGP 39393. Circulation 1994;90:1-569.
ดาวน์โหลด
เผยแพร่แล้ว
ฉบับ
ประเภทบทความ
สัญญาอนุญาต
อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
